

$$= 1.22 \times 10^{-10} \text{ s}^{-1}$$

Table 1. *Continued*

====

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
84

$$= 2 \cdot 10^{11} \text{ Hz} \cdot \text{m}^{-1} \cdot \text{m}^{-1} \cdot \text{m}^{-1} = 2 \cdot 10^{11} \text{ Hz} \cdot \text{m}^{-1} \cdot \text{m}^{-1} = 2 \cdot 10^{11} \text{ Hz} \cdot \text{m}^{-1} \cdot \text{m}^{-1}$$

124. ANSWER 1 OF 12 HEADLINE COPYRIGHT 2007 ACS  
 ATTENTION NUMBER: 2007414 HEADLINE  
 DOCUMENT NUMBER: 155:207491  
 TITLE: Monomeric and dimeric EsRed  
 fluorescent protein variants and  
 cDNAs and methods for preparing and using the proteins  
 INVENTOR(S): Tsien, Roger Y.; Campbell, Robert E.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 67 pp., Cont.-in-part of U.S.  
 Pat. Appl. 2003 32,688.  
 CODEN: USXWCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003-086608	B1	20030527	US 2001-121838	20020417
US 2003-086609	B1	20030527	US 2001-166606	20020714
PRIORITY AFFILI. INFO.:			US 2001-084387	20010227
			US 2001-066558	20010524

AB The present invention relates to monomeric and dimeric forms of Anthrax fluorescent proteins, esp. *Plasmodium* DsRed. The invention also relates to methods of making such fluorescent protein monomers and dimers using, for example, error-prone PCR. The improved fluorescent proteins may be used for assaying transcription as well as for anal. of in vivo localization or trafficking of proteins. Thus, DsRed variants which are longer tetramers but instead form dimers, or exist as monomers were produced. The monomeric variant mRFP1 matures rapidly and has minimal emission when excited at wavelengths optimal for GFP. Application of antibodies paired with the DsRed system to nonproliferative GFP infected cells GFP variants which are longer tetramers.

INV. ANSWER: YES  
 ADDRESS NUMBER: 100-116977  
 DOCUMENT NUMBER: 100-116980  
 TITLE: Dimeric fusion products of fluorescent proteins showing low levels of oligomerization  
 INVENTOR: Tsien, Roger Y.; Campbell, Robert E.  
 PATENT ATTORNEY: N/A  
 OFFICE: U.S. Pat. Appl. 1987, 4, 11, 100-116977 & 100-116980  
 Ser. No. 19, 100-  
 CLASS: C12N 1/21  
 SUBJECT: Patent  
 EXAMINEE: EXAMINEE  
 COMMENTS: FAMILY AND OTHER INFO:  
 PATENT INFORMATION:  
 7/1/85

PATENT NO.	KIND	DATE	AFFILIATION NO.	DATE
NO. 1,234,567	A1	2010-12-15	NO. 1-100-1234	2010-12-24
NO. 1,234,568	A2	2010-12-16	NO. 2-100-1235	2010-12-25
NO. 1,234,569	A1	2010-12-17		

[illegible]

US 2008-59485 A1 20080327 US 2002-121258 20020410  
PRIORITY APPLN. INFO.: US 2001-794386 A2 20010226  
US 2001-866538 A 20010524

AB Fluorescent proteins, such as green fluorescent protein, that show lower degrees of oligomerization are described for anal. use. The non-oligomerizing derivs. are fusion proteins of fluorescent proteins including a naturally occurring green fluorescent protein, a red fluorescent protein or derivs. that are dimers or the fluorescent protein connected by a linker peptide. The protein may also carry other modifications, such as in surface residues, that prevent oligomerization without a significant impact on fluorescence properties. Also provided is a fusion protein, which includes a non-oligomerizing fluorescent protein linked to at least one polypeptide of interest. Chimeric genes encoding these fusion proteins and expression constructs and hosts for the genes are also described.

22. ANSWER : OF 10 HEADPLS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:67017 HEADPLS  
DOCUMENT NUMBER: 137:11305  
TITLE: Non-Fluorophore-Induced Fluorescent Proteins and their use  
INVENTOR : Tsien, Roger Y.; Baird, William A.;  
Campbell, Robert E.; Zacharias, David A.  
PATENT APPLICANT : The Regents of the University of California, USA  
PUBLISHED : 1999 Apr 1, 11:31  
PUBLISHED IN: ENGLISH  
DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY AND SERIAL NUMBER:  
PATENT INFORMATION:

5 100-100

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4,122,000	A	12/15/77	US 3,812,000	12/15/77
US 4,122,001	A	12/15/77	US 3,812,001	12/15/77
AB: AL, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BX, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DC, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GG, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LL, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MM, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ.				
US 4,122,002	A	12/15/77	US 3,812,002	12/15/77
US 4,122,003	A	12/15/77	US 3,812,003	12/15/77
US 4,122,004	A	12/15/77	US 3,812,004	12/15/77
US 4,122,005	A	12/15/77	US 3,812,005	12/15/77
US 4,122,006	A	12/15/77	US 3,812,006	12/15/77
US 4,122,007	A	12/15/77	US 3,812,007	12/15/77
US 4,122,008	A	12/15/77	US 3,812,008	12/15/77
US 4,122,009	A	12/15/77	US 3,812,009	12/15/77
US 4,122,010	A	12/15/77	US 3,812,010	12/15/77
US 4,122,011	A	12/15/77	US 3,812,011	12/15/77
US 4,122,012	A	12/15/77	US 3,812,012	12/15/77
US 4,122,013	A	12/15/77	US 3,812,013	12/15/77
US 4,122,014	A	12/15/77	US 3,812,014	12/15/77
US 4,122,015	A	12/15/77	US 3,812,015	12/15/77
US 4,122,016	A	12/15/77	US 3,812,016	12/15/77
US 4,122,017	A	12/15/77	US 3,812,017	12/15/77
US 4,122,018	A	12/15/77	US 3,812,018	12/15/77
US 4,122,019	A	12/15/77	US 3,812,019	12/15/77
US 4,122,020	A	12/15/77	US 3,812,020	12/15/77
US 4,122,021	A	12/15/77	US 3,812,021	12/15/77
US 4,122,022	A	12/15/77	US 3,812,022	12/15/77
US 4,122,023	A	12/15/77	US 3,812,023	12/15/77
US 4,122,024	A	12/15/77	US 3,812,024	12/15/77
US 4,122,025	A	12/15/77	US 3,812,025	12/15/77
US 4,122,026	A	12/15/77	US 3,812,026	12/15/77
US 4,122,027	A	12/15/77	US 3,812,027	12/15/77
US 4,122,028	A	12/15/77	US 3,812,028	12/15/77
US 4,122,029	A	12/15/77	US 3,812,029	12/15/77
US 4,122,030	A	12/15/77	US 3,812,030	12/15/77
US 4,122,031	A	12/15/77	US 3,812,031	12/15/77
US 4,122,032	A	12/15/77	US 3,812,032	12/15/77
US 4,122,033	A	12/15/77	US 3,812,033	12/15/77
US 4,122,034	A	12/15/77	US 3,812,034	12/15/77
US 4,122,035	A	12/15/77	US 3,812,035	12/15/77
US 4,122,036	A	12/15/77	US 3,812,036	12/15/77
US 4,122,037	A	12/15/77	US 3,812,037	12/15/77
US 4,122,038	A	12/15/77	US 3,812,038	12/15/77
US 4,122,039	A	12/15/77	US 3,812,039	12/15/77
US 4,122,040	A	12/15/77	US 3,812,040	12/15/77
US 4,122,041	A	12/15/77	US 3,812,041	12/15/77
US 4,122,042	A	12/15/77	US 3,812,042	12/15/77
US 4,122,043	A	12/15/77	US 3,812,043	12/15/77
US 4,122,044	A	12/15/77	US 3,812,044	12/15/77
US 4,122,045	A	12/15/77	US 3,812,045	12/15/77
US 4,122,046	A	12/15/77	US 3,812,046	12/15/77
US 4,122,047	A	12/15/77	US 3,812,047	12/15/77
US 4,122,048	A	12/15/77	US 3,812,048	12/15/77
US 4,122,049	A	12/15/77	US 3,812,049	12/15/77
US 4,122,050	A	12/15/77	US 3,812,050	12/15/77
US 4,122,051	A	12/15/77	US 3,812,051	12/15/77
US 4,122,052	A	12/15/77	US 3,812,052	12/15/77
US 4,122,053	A	12/15/77	US 3,812,053	12/15/77
US 4,122,054	A	12/15/77	US 3,812,054	12/15/77
US 4,122,055	A	12/15/77	US 3,812,055	12/15/77
US 4,122,056	A	12/15/77	US 3,812,056	12/15/77
US 4,122,057	A	12/15/77	US 3,812,057	12/15/77
US 4,122,058	A	12/15/77	US 3,812,058	12/15/77
US 4,122,059	A	12/15/77	US 3,812,059	12/15/77
US 4,122,060	A	12/15/77	US 3,812,060	12/15/77
US 4,122,061	A	12/15/77	US 3,812,061	12/15/77
US 4,122,062	A	12/15/77	US 3,812,062	12/15/77
US 4,122,063	A	12/15/77	US 3,812,063	12/15/77
US 4,122,064	A	12/15/77	US 3,812,064	12/15/77
US 4,122,065	A	12/15/77	US 3,812,065	12/15/77
US 4,122,066	A	12/15/77	US 3,812,066	12/15/77
US 4,122,067	A	12/15/77	US 3,812,067	12/15/77
US 4,122,068	A	12/15/77	US 3,812,068	12/15/77
US 4,122,069	A	12/15/77	US 3,812,069	12/15/77
US 4,122,070	A	12/15/77	US 3,812,070	12/15/77
US 4,122,071	A	12/15/77	US 3,812,071	12/15/77
US 4,122,072	A	12/15/77	US 3,812,072	12/15/77
US 4,122,073	A	12/15/77	US 3,812,073	12/15/77
US 4,122,074	A	12/15/77	US 3,812,074	12/15/77
US 4,122,075	A	12/15/77	US 3,812,075	12/15/77
US 4,122,076	A	12/15/77	US 3,812,076	12/15/77
US 4,122,077	A	12/15/77	US 3,812,077	12/15/77
US 4,122,078	A	12/15/77	US 3,812,078	12/15/77
US 4,122,079	A	12/15/77	US 3,812,079	12/15/77
US 4,122,080	A	12/15/77	US 3,812,080	12/15/77
US 4,122,081	A	12/15/77	US 3,812,081	12/15/77
US 4,122,082	A	12/15/77	US 3,812,082	12/15/77
US 4,122,083	A	12/15/77	US 3,812,083	12/15/77
US 4,122,084	A	12/15/77	US 3,812,084	12/15/77
US 4,122,085	A	12/15/77	US 3,812,085	12/15/77
US 4,122,086	A	12/15/77	US 3,812,086	12/15/77
US 4,122,087	A	12/15/77	US 3,812,087	12/15/77
US 4,122,088	A	12/15/77	US 3,812,088	12/15/77
US 4,122,089	A	12/15/77	US 3,812,089	12/15/77
US 4,122,090	A	12/15/77	US 3,812,090	12/15/77
US 4,122,091	A	12/15/77	US 3,812,091	12/15/77
US 4,122,092	A	12/15/77	US 3,812,092	12/15/77
US 4,122,093	A	12/15/77	US 3,812,093	12/15/77
US 4,122,094	A	12/15/77	US 3,812,094	12/15/77
US 4,122,095	A	12/15/77	US 3,812,095	12/15/77
US 4,122,096	A	12/15/77	US 3,812,096	12/15/77
US 4,122,097	A	12/15/77	US 3,812,097	12/15/77
US 4,122,098	A	12/15/77	US 3,812,098	12/15/77
US 4,122,099	A	12/15/77	US 3,812,099	12/15/77
US 4,122,100	A	12/15/77	US 3,812,100	12/15/77

AB: Non-oligomerizing fluorescent proteins, which are operatively operatively linked to a non-oligomerizing protein, or which are derived from a fluorescent protein having at least one mutation that renders it incapable of oligomerizing, are provided. The non-oligomerizing fluorescent proteins can be derived from a naturally occurring green fluorescent protein, a red fluorescent protein, or other fluorescent protein, or a fluorescent protein derived therefrom. Also provided is a fusion protein, which includes a non-oligomerizing fluorescent protein linked to at least one polypeptide of interest. In addn., a polynucleotide encoding a non-oligomerizing fluorescent protein is provided, as is a recombinant nucleic acid mol., which includes polynucleotide encoding a non-oligomerizing fluorescent protein operatively linked to at least a second polynucleotide. Vectors and host cells contg. such polynucleotides also are provided, as are kits contg. one or more non-oligomerizing fluorescent proteins or encoding polynucleotides or constructs derived therefrom. Further provided are methods of making and using the proteins and polynucleotides, e.g., to detect pH in cells or bial. tissues, to detect the presence or activity of enzymes, to identify agents or conditions which regulate the activity of an expression control sequence, and to identify interactions of a first and second mol. Thus, residues 220-alanine, 221-leucine, and 223-phenylalanine were shown to be involved in oligomerization of GFP. Substitution of charged amino acids (e.g., lysine, arginine) for these residues prevented oligomerization.

111 ANSWER 1 OF 12 MEDLINE PUBLICATION  
 ABSTRACT NUMBER: 2, 117845 MEDLINE  
 DOCUMENT NUMBER: 2, 117845 MEDLINE  
 TITLE: A non-oligomerizing red fluorescent protein.  
 AUTHOR: Campbell Robert E; Tsien Roger Y; Palmer Amy E; Steinbach Paul A; Baird George J; Zacharias David A;  
 CORPORATE SOURCE: Department of Pharmacology, University of California at San Diego, 3550 La Jolla Village Drive, La Jolla, CA 92037, USA.  
 CONTRACT NUMBER: N01-CA-341-15-0001  
 SOURCE: FROM MEDLINE OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991 MAR 11 09:11 00-00-00.

File: 10000000

Journal Code: 0000-0000, ISSN: 0000-0000.  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; JOURNAL ARTICLE  
LANGUAGE: English  
FILE COMMENT: Priority Journals  
ORIGIN SOURCE: GENBANK-AFL 0000; GENBANK-AFL 0000; GENBANK-AFL 0000  
ENTRY NUMBER: 10000000  
ENTRY DATE: Entered STN: 10000000  
Last Updated: 10000000  
Entered Medline: 10000000

AB All fluorescent proteins (FPs) have display some form of tertiary structure, including the weak tendency to aggregate. **green fluorescent protein (GFP)** dimerize, the relative dimerization of **benilla GFP**, and the relative dimerization of the red fluorescent protein **red fluorescent protein (RFP)**. Although the weak dimerization of **benilla GFP** has not improved its acceptance as an indispensable tool in cell biology, the relative dimerization of **benilla** has greatly hindered its use as a genetically encoded fusion tag. We present here the stepwise evolution of **benilla** to a dimer and then either to a genetic fusion of two copies of the protein, **benilla**, or to a tandem dimer, or to a true monomer designated **mRFP1** (monomeric red fluorescent protein). Each subunit interface was disrupted by insertion of a **benilla**, which initially supplied the resulting protein, but the **benilla** was subsequently removed by random and directed mutagenesis resulting in **benilla** mutations in the dimer and in **mRFP1**. Purification of the **benilla** function protein **benilla** to **mRFP1** dimerally functional. **benilla**, **benilla** analogous fusion to the tetramer and dimer dimer. Although **mRFP1** has somewhat lower extinction coefficient, quantum yield, and photostability than **benilla**, **mRFP1** matures 10 times faster, so that it shows similar brightness in living cells. In addition, the excitation and emission peaks of **mRFP1**, 584 and 607 nm, are approximately 25 nm red-shifted from **benilla**, which should confer greater tissue penetration and spectral separation from autofluorescence and other fluorescent proteins.

121 ANSWER 3 OF 10 MEDLINE DUPLICATE 2  
ACCESSION NUMBER: 10000000 MEDLINE  
COMMENT NUMBER: 10000000 PubMed ID: 10000000  
TITLE: Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells.  
COMMENT: Comment in: Science. 2002 May 3;296(5569):913-6.  
AUTHOR: Zacharias David A; Violin Jonathan B; Newton Alexandra C; Tsien Roger Y  
CORPORATE SOURCE: Department of Pharmacology, Biomedical Sciences Graduate Program, and, Howard Hughes Medical Institute, University of California, San Diego, La Jolla, CA 92093-0400, USA.  
CONTRACT NUMBER: 10000000 NIGMS  
10000000 (NIGMS)  
10000000 (NIGMS)  
SOURCE: SCIENCE, (2002 May 3) 296 (5569) 913-6.  
Journal code: 0000-0000, ISSN: 0000-0000.  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; JOURNAL ARTICLE  
LANGUAGE: English  
FILE COMMENT: Priority Journals  
ENTRY NUMBER: 10000000  
ENTRY DATE: Entered STN: 10000000  
Last Updated: 10000000  
Entered Medline: 10000000

AB Many proteins associated with the plasma membrane are known to partition

Figure 1. The effect of the concentration of the *Agaricus bisporus* spores on the growth of *Agaricus bisporus* and *Agaricus bisporus* spores on the growth of *Agaricus bisporus* spores.

[illegible][illegible]

**AUTHORS:** Cooper, Stephen L.; Brown, Stephen R.; Anderson,  
Christopher M.; Campbell, R. Duncan (1)

ORGANIZATION: 1. Functional Genomics Group, MRC UK HMM Res. Unit, Centre,  
Biostat, Cambridge, UK. E-mail: [christopher.humphreys@mrc.ac.uk](mailto:christopher.humphreys@mrc.ac.uk)

[illegible]

1. *Chlorophyll a* and *Chlorophyll b* were determined by the method of Arar and Collins (1971) using a Shimadzu 1010 spectrophotometer.

1. *Chlorophyll a* and *Chlorophyll b* were determined by the method of Arar and Collins (1971) using a Shimadzu 1010 UV-Visible Spectrophotometer.

AB The inhibitory kappaB (IkappaB)-like (IkappaBL) gene is located within the class III region of the MHC on human chromosome 6. Previous analysis of the predicted amino acid sequence of the human IkappaBL protein revealed three putative functional domains; two ankyrin repeat sequences, which are similar to the second and third ankyrin repeats of the nuclear factor kappaB (NF-kappaB) protein; three PEST sequence motifs (a sequence that is rich in proline, serine, aspartic acid and threonine residues), which are also found in other IkappaB family members; and a C-terminal leucine zipper-like motif. In the present study we have identified a novel bipartite motif, which is required for nuclear localization of the IkappaBL protein. Analyses of IkappaBL-specific transcripts revealed the existence of a widely expressed splice variant form of IkappaBL (IkappaBLs1), which lacks the amino acid sequence SELESAWPKLKKRFF, where single-letter amino-acid notation has been used. Interestingly, translation of IkappaBL mRNA in vivo was found to initiate predominantly from the second available methionine, thereby resulting in the disruption of the predicted N-terminal PEST sequence. Also, transient expression of T7-epitope-tagged IkappaBL and IkappaBLs1 proteins in mammalian cells showed that both proteins were targeted to the nucleus, where they accumulate in nuclear speckles. To define the protein domains required for nuclear import and subnuclear localization, a complementary set of deletion mutants and enhanced green fluorescent protein-IkappaBL domain fusions were expressed in mammalian cells. Data from these experiments show that a combination of the ankyrin-repeat region and an adjacent arginine-rich sequence are necessary and sufficient for both nuclear import and speckle localization.

[illegible][illegible]

and the  $\beta$  parameter is the inverse of the variance of the error term. The  $\beta$  parameter is estimated by the following equation:

TITLE: Medicine: green the research protocol  
 FROM: 1998

Tsien, Roger Y.; Hsiao, Hsueh-

PATENT ASSIGNEE C : Reports of the University of California, INC  
 OFFICE: U.S., 21 11, Cont.-in-part of U.S. 5,440,441.  
 INVENTOR: TSCHAK  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY APP. NUM. & CNT: 3  
 PATENT INFORMATION:

PATENT N.	KIND	DATE	APPLICATION N.	DATE
US 5,440,441	B1	21 11 11	US 1994-337915	19941111
US 5,440,442	B1	21 11 11	US 1994-337915	19941111
CA 2,343,886	AA	19960818	CA 1995-2343886	19951113
WO 96/13,117	A1	19960818	WO 1996-2343886	19961113
K: AL, AM, AN, AO, BB, BG, BR, BY, CA, CH, CN, CO, DE, DK, EE, EG, FI, GE, GR, HU, IE, JP, KE, KG, KR, KZ, LA, LB, LS, LT, LU, LV, MD, ME, MK, MN, MX, NG, NZ, PL, PT, RO, SI, SE, SG, SI, SK PW: HE, LC, NK, SD, SZ, TG, AT, BL, CH, DE, DK, EG, FR, GE, GR, IE, IT, LI, NL, NL, PT, SE, BF, EC, GF, GG, GI, GN, HA, HN, ML, MR, NE, SN, TS, TG EP 11 47098 A2 20010606 EP 2001-105911 19961113 EP 11 47098 A3 20020918 S: AT, BE, CH, DE, DK, EC, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE US 1994-337915 A 19940807 US 1996-753143 19961123 PRIORITY APPL. INFO.: US 1994-337915 A 19941110 WO 1995-2343886 W 19951113 CA 1995-2343886 A3 19951113 EP 1995-939898 A3 19951113 US 1996-753143 A 19961123				

AB Modifications in the sequence of Aequorea wild-type GFP provide products having markedly different excitation and emission spectra from corresponding products from wild-type GFP. In one class of modifications, the product derived from the modified GFP exhibits an alteration in the ratio of two main excitation peaks obsd. with the product derived from wild-type GFP. In another class, the product derived from the modified GFP fluoresces at a shorter wavelength than the corresponding product from wild-type GFP. In yet another class of modifications, the product derived from the modified GFP exhibits only a single excitation peak and enhanced emission relative to the product derived from wild-type GFP.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER # OF 18 MEDLINE DUPLICATE 3  
 ACCESSION NUMBER: 2001429679 MEDLINE  
 DOCUMENT NUMBER: 21369953 PubMed ID: 11387331  
 TITLE: Reducing the environmental sensitivity of yellow fluorescent protein. Mechanism and applications.  
 AUTHOR: Griesbeck O; Baird S S; Campbell R E; Zacharias D A; Tsien R Y  
 CORPORATE SOURCE: Howard Hughes Medical Institute, University of California, San Diego, La Jolla, California 92093-0647, USA.  
 CONTRACT NUMBER: EP/CA23109-16 (NCI)  
 JOURNAL: JOURNAL OF BIOLOGICAL CHEMISTRY, 273(1):1-11, 1998.  
 JOURNAL CODE: 0021-9105. ISSN: 0021-9105.

[illegible]

LAW ANSWER : OF 17 HARBUS COPYRIGHT 20 - ASS  
 ACCESSION NUMBER: 2001:657326 HARBUS  
 DOCUMENT NUMBER: 136:321466  
 TITLE: Fluorescence resonance energy transfer analysis of cell surface receptor interactions and signalling using spectral variants of the **green** fluorescent protein  
 AUTHOR(S): Chan, Francis Ka-Ming; Siegel, Richard M.; Zacharias, David; Swartz, John; Holmes, Kevin L.; **Tsien, Roger Y.**; Leonards, Michael L.  
 CORPORATE SOURCE: Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892-1492, USA  
 SOURCE: Cytometry 12(11), 44-47, 361-363  
 COPEN: COT03Q; ISBN: 0190-4766  
 PUBLISHER: Wiley-Liss, Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

**ABSTRACT**

Fluorescence resonance energy transfer (FRET) is a powerful technique for measuring molecular interactions at Angstrom distances. We present a new method of FRET that utilizes the unique spectral properties of variants of the green fluorescent protein (GFP). The large-scale production of GFP by flow cytometry, the proteins of interest are fused to GFP, and the green fluorescent protein (GFP) is the yellow fluorescent protein (YFP). FRET between these differentially tagged fusion proteins is analyzed using a dual-laser fluorescence cytometer. We show that quantitative measurements of individual receptor chains at single molecules can be achieved. GFP-tagged receptors can be detected as FRET from GFP-tagged receptor channels to YFP-tagged receptor chains. In addition, we

FILE NUMBER: 1. P 17. HAWKING COPYRIGHT 1980 AND  
 ABBREVIATION NUMBER: 174:14213. HAWKING  
 DOCUMENT NUMBER: 174:14213  
 TITLE: Green fluorescent protein molecule containing  
 oligo-nitrobenzyl ester peptides for use as reporter  
 moieties  
 INVENTOR(S): Tsien, Roger Y.; Palmer, Geoffrey A.  
 PATENT APPLICATION: Pending at the University of California, USA  
 COUNTRY: USA  
 CODEN: BIXND2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY APP. NO. JAPAN: 5  
 PATENT AND PUBL. NO:

AB The present invention provides polypeptides and polynucleotides encoding fluorescent indicators having inserted within a fluorescent moiety a gene for polypeptide. The proteins are derived, that are not normally fluorescent, present a FRET coupling, -binding of a ligand, the presence of which in a conformational change, and an increase in the resonance of the protein. Also provided are methods of using the fluorescent indicators. Specifically provided are fluorescent indicators and



123 ANSWER 12 OF 14 HEALING COPYRIGHT 2014 ACS  
 ACCESSION NUMBER: 1000140115 HEALING  
 DOCUMENT NUMBER: 1000140115  
 TITLE: A genetically encoded, fluorescent indicator for  
 cytosolic AMP in living cells  
 AUTHOR: Jacobi, Marcell; Di Girola, Francesca; Cho, Charles  
 Y.; Feng, Luxin; Knapp, Tim; Needleman, Paul A.;  
 Taylor, Susan J.; Tsien, Roger Y.; Pennan,  
 Tania  
 ORIGINATOR: Department of Experimental Biomedical Sciences,  
 University of Padua, Padua, 35131, Italy  
 SOURCE: Nature Cell Biology 2009, 11, 13-21  
 ISSN: NORTON; ISSN: 1474-7865  
 PUBLISHER: Humana Press

[illegible]

AB In GMM, virtually all signaling cascades within cells, and therefore in the world, in this second messenger have an essential role in many cellular events. How do we achieve a new paradigm, in which the signaling cascade is GMM in living cells. By turning the GMM into a protein kinase A with the variable **green** fluorescent protein activity, we have achieved a system in which the fluorescently regulated energy transfer between the two fluorescent proteins is dependent on the levels of GMM. This paradigm will point the way to the development of the next generation of GMM in life.

1. The first step is to identify the problem. In this case, the problem is that the company is not meeting its sales targets.

Year	Age	Sex	Location	Species	Number	Percentage	Notes
1998	10	M	...	...	...	...	...
1999	11	F	...	...	...	...	...
2000	12	M	...	...	...	...	...
2001	13	F	...	...	...	...	...
2002	14	M	...	...	...	...	...
2003	15	F	...	...	...	...	...
2004	16	M	...	...	...	...	...
2005	17	F	...	...	...	...	...
2006	18	M	...	...	...	...	...
2007	19	F	...	...	...	...	...
2008	20	M	...	...	...	...	...
2009	21	F	...	...	...	...	...
2010	22	M	...	...	...	...	...
2011	23	F	...	...	...	...	...
2012	24	M	...	...	...	...	...
2013	25	F	...	...	...	...	...
2014	26	M	...	...	...	...	...
2015	27	F	...	...	...	...	...
2016	28	M	...	...	...	...	...
2017	29	F	...	...	...	...	...
2018	30	M	...	...	...	...	...
2019	31	F	...	...	...	...	...
2020	32	M	...	...	...	...	...

[illegible]

REMARKS: Monitor for cyanosis by posturing + green  
 + increased protein in urine in the future + cyanosis  
 + edema.

Author: H. S. G. Hsu, M. J. Li, T. Tsien, R. W.

[illegible]

Society for Neuroscience Abstracts, 1999, Vol. 25, Part 1, p. 15.  
 15, pg. Abstract N. 154.1 print.  
 Meeting Info.: 7th Annual Meeting of the Society of  
 Neuroscience, New Orleans, LA, USA November 4-9, 1999.  
 Society for Neuroscience  
 Tel: 813-326-8245.

2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 2679, 2680, 2681, 26

[illegible]

**SUBJECTS** The subjects were 10 male students from the University of Illinois at Chicago who had no previous experience with the apparatus or task.

AB FM dyes allow fluorescence imaging of active presynaptic terminals and provide valuable insights into dynamics of vesicular turnover, but are not ideally suited for studying the kinetics of exocytosis. FM1-43, for example, requires approx 3 s to depart from the membrane. To selectively monitor exocytosis independent of endocytosis we have developed a new approach based on the quenching of a fluorophore permanently held within the vesicle lumen by a probe that enters vesicles upon fusion. The fluorophore is green fluorescent protein (GFP) associated with the luminal domain of VAMP (synaptobrevin-2), introduced by transfection, and the quencher is promethenol blue (PMB), a small, hydrophilic molecule. In quenching experiments, boutons were first exposed to PMB in  $\text{Ca}^{2+}$ -free Tyrode to eliminate fluorescence of any VAMP-GFP that had somehow been stranded on the plasma membrane. Subsequent exposure to 2 mM  $\text{K}^{+}$  and 1 mM  $\text{Ca}^{2+}$  to induce voltage-gated  $\text{Ca}^{2+}$  entry caused sharp drop in GFP fluorescence ( $n=7$ ), with biphasic kinetics reminiscent of restoration of FM1-43. In contrast, high  $\text{K}^{+}$   $\text{Ca}^{2+}$  stimulation in the absence of PMB failed to decrease the fluorescence of puncta, even though a later repeat of the same challenge in PMB caused clear decreases in fluorescence in the same puncta ( $n=8$ ). Evidently, pH increases during exocytosis had no significant effect on the fluorescence of this GFP construct. When PMB-labeled boutons were subjected to high  $\text{K}^{+}$   $\text{Ca}^{2+}$  stimulation in the absence of PMB, the fluorescence of puncta suddenly increased next, as expected if PMB had escaped from vesicles undergoing fusion. One advantage of this approach is that VAMP-GFP can mark boutons even if they are functionally silent. The exocytosis of pinched-off vesicles causes a fluorescence increase, a convenient trick for picking out signals against background noise. Extending this approach to membranes of different sizes

Pub. No. 5,442,442

Pub. No. 5,442,442 is the subject of a patent application filed with the U.S. Patent and Trademark Office.

1. ANSWER TO OFFICE ACTION: RECAPITULATED COPYRIGHT 2000 AND

ADDITIONAL NUMBER: 1999:714-75 RECAPITULATED

DOCUMENT NUMBER: 131:349774

TITLE: **Green fluorescent proteins for measuring intracellular pH in a biological sample**

INVENTOR(S): **Tsien, Roger Y.; Li, Jie; Tsien, Roger; Winkler, Robert M.**

PATENT ASSIGNEE(S): **The Regents of the University of California, USA; University of Illinois**

SOURCE: **U.S. Pat. Appl., 1999**

CLASS: **680:0000**

LANGUAGE: **English**

FAMILY APP. NOS. (S): **2**

PATENT INFO RELAT(S):

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

U.S. Pat. No. 5,442,442	A	1999-11-11	U.S. Pat. No. 5,442,442	1999-11-11
-------------------------	---	------------	-------------------------	------------

Search completed by David H. Hoelzer 11-11-99

[illegible]

FILE NUMBER: 17-00000  
ACCESSION NUMBER: 17-00000  
DOCUMENT NUMBER: 17-00000  
TITLE: Molecular Organization and Replication of DNA  
green fluorescent protein.  
AUTHOR: Ellis G J; Zacharias R A; Tsien R Y  
ORGANIZATION: Department of Immunology, University of California at San Diego,  
La Jolla, CA 92037, USA.  
CONTRACT NUMBER:  
SOURCE: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE  
UNITED STATES OF AMERICA, 1998 Vol 95 No 16 9141-...  
Journal Code: 7808870. ISSN: 0027-8424.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; [JOURNAL ARTICLE]  
LANGUAGE: English  
FILE COMMENT: Priority Journals  
ENTRY MONTH: 1998  
ENTRY DATE: Entered STN: 1998111  
Last Updated on STN: 19981101  
Expanded Edition: 19981101

As many areas of biology and biotechnology have been revolutionized by the ability to label proteins genetically by fusion to the Acquired: green fluorescent protein  
GFP. In previous fusions, the GFP has been treated as an indivisible entity, usually appended to the amino or carboxyl terminus of the target protein, occasionally inserted within the host sequence. The tightly intertwined, three-dimensional structure and intricate posttranslational self-modification required for chromophore formation would prevent the major rearrangements or insertions within GFP which prevent fluorescence. However, we now show that several rearrangements of GFPs, in which the amino and carboxyl portions are interchanged and rejoined with a short spacer connecting the original termini, still remain fluorescent. These circular permutations have altered pKa values and orientations of the chromophore with respect to a bound partner. Furthermore, certain locations within GFP tolerate insertion of entire proteins, and conformational changes in the bound partner can be followed off-site in the fluorescent protein. For example, insertions of alkali or a zinc finger remain in place: Tyr-145 of a yellow variant enhanced yellow fluorescent protein is GFP fluorescent, indicating that the whole chromophore can be enhanced.

[illegible]

... ..

*Journal of Management Education* 30(6)p. 789-804



11. A fusion protein coding sequence by a linker that includes a cleavage site for trypsin, chymotrypsin and enterokinase was prepared by expressing the gene in *Escherichia coli*. The fusion protein shows strong green fluorescence. When cleaved by trypsin, the green emission disappears almost completely and is replaced by a blue emission. The individual green and blue fluorescent proteins showed no changes in fluorescence indicating that they were resistant to trypsin.

12. AUTHOR: T. S. Hsiao, M. J. Hsiao, M. J. Hsiao, M. J. Hsiao

13. AUTHOR: T. S. Hsiao, M. J. Hsiao, M. J. Hsiao, M. J. Hsiao

14. TITLE: Fluorescent measurement of intracellular signal transduction: Applications to pharmaceutical screening.

15. AUTHOR: T. S. Hsiao, M. J. Hsiao, M. J. Hsiao, M. J. Hsiao

16. AUTHOR: T. S. Hsiao, M. J. Hsiao, M. J. Hsiao, M. J. Hsiao

17. CORPORATE SOURCE: Howard Hughes Med. Inst., 7500, N. 11th, VA, 22101, USA

18. SOURCE: B. S. Abstracts, 1984, 12th National Meeting, San Francisco, April 13-17, 1984, 12th-474. American Chemical Society: Washington, D. C.

19. SOURCE: 644000

20. DOCUMENT TYPE: Conference; Meeting Abstract

21. LANGUAGE: English

AB Fluorescent measurement of intracellular signal transduction, together with construction of responsive cell lines and miniaturized parallel assays, provide some promising approaches to ultra-high-throughput screening of pharmaceutical libraries. A) Proteins can be fluorescently tagged in vivo by fusion to Green Fluorescent Protein (GFP). Mutagenesis, aided in part by the crystal structure, has improved GFP and yielded new colors, which reveal protein-protein interaction and protease activity by fluorescence resonance energy transfer (FRET). B) Gene expression can be visualized in single living cells by using beta-lactamase as a reporter enzyme. It cleaves novel membrane-permeant substrates and changes their fluorescence from green to blue by liberating FRET. Because of its enzymic amplification and non-destructive assay, beta-lactamase has major advantages over existing reporter genes. C) A fast and sensitive optical readout of membrane voltage results from FRET between a fluorescent gating charge and another fluorophore attached to the inside of the membrane.

22. SOURCE: 123

23. SOURCE: 123

24. SOURCE: 123

25. SOURCE: 123

26. SOURCE: 123

27. SOURCE: 123

28. SOURCE: 123

29. SOURCE: 123

30. SOURCE: 123

31. SOURCE: 123

32. SOURCE: 123

33. SOURCE: 123

34. SOURCE: 123

35. SOURCE: 123

36. SOURCE: 123

[illegible]

Journal of Interpersonal Violence 26(12)



10. ANSWER : 4.04 KEYLINE  
 ABBREVIATION NUMBER: 4.0411 KEYLINE  
 DOCUMENT NUMBER: 4.0411-1000-11-1000-11  
 TITLE: Intracellular localization of Herpes simplex virus type 1  
 thymidine kinase-coded different fluorescent proteins  
 specific to different reservoirs.  
 AUTHOR: J. Ariane; J. Andreas; R. Nikolai  
 CORPORATE SOURCE: Molecular Neurooncology Laboratory, Department of  
 Neurosurgery, Martin-Luther-University Halle-Wittenberg,  
 Heinrich-Jaeger-Strasse 1, 06107, Halle, Germany.  
 ariane.j@medizin.uni-halle.de

[illegible]

# 1. Oligomerization of membrane- and G-protein-coupled receptors.

EMBL ANKER: 4 OF 24 MEDLINE  
 ACCESSION NUMBER: 11111111 MEDLINE  
 DOCUMENT NUMBER: 11111111 PubMed ID: 11111111  
 TITLE: Measurement of changes in fluorescence resonance energy transfer between microaggregates of receptor in response to agonists.  
 AUTHOR: Cohen, Anna; Van E. Michael  
 CORPORATE SOURCE: Johns Hopkins University School of Medicine and Johns Hopkins University, Baltimore, MD, USA.  
 SOURCE: METHODS, 12/12 Aug, 1994, 614-62.  
 JOURNAL: J Biol Chem 269:11111-11112, 1994.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal Article; Journal Article  
 LANGUAGE: English  
 FILE OF SOURCE: Primary Journals  
 ENTRY NUMBER: 111111  
 ENTRY PATH: Entered JCN: 111111  
 Last Updated in JCN: 111111  
 Entered Medline: 111111

**Abstract:** Oligomerization of membrane- and G-protein-coupled receptors has recently emerged as an important step in cellular signaling. Fluorescence resonance energy transfer (FRET) has been used previously as the method of choice for demonstrating in vivo protein-protein interactions and receptor oligomerization. We have used oligomers of green fluorescent proteins (GFP) to investigate receptor dimerization in relation to receptor activation. Two pairs of FRET-compatible fluorescent proteins were used: mCherry with YFP, and enhanced green fluorescent protein (EGFP) with dsRed. Changes in the ratio between acceptor and donor fluorescence were measured after addition of buserelin, a GnRH agonist, and antide, a GnRH antagonist. For both pairs of fluorescent proteins, an increase in the ratio of acceptor to donor intensities was observed immediately after addition of buserelin, as would be predicted if FRET occurred due to the microaggregation of receptors conjugated with different fluorescent proteins. No change in FRET was observed in time for cells in medium or after addition of antide. The increase in FRET signal was not uniform throughout a cell.

EMBL ANKER: 4 OF 24 MEDLINE  
 ACCESSION NUMBER: 11111111 MEDLINE  
 DOCUMENT NUMBER: 11111111 PubMed ID: 11111111  
 TITLE: Use of fluorescence resonance energy transfer to analyze oligomerization of G-protein-coupled receptors expressed in yeast.  
 AUTHOR: Robert A. Mark; Blumer-Kendall J  
 CORPORATE SOURCE: Department of Cell Biology and Physiology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.  
 SOURCE: METHODS, 12/12 Aug, 1994, 614-62.  
 JOURNAL: J Biol Chem 269:11111-11112, 1994.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal Article; Journal Article  
 LANGUAGE: English  
 FILE OF SOURCE: Primary Journals  
 ENTRY NUMBER: 111111  
 ENTRY PATH: Entered JCN: 111111  
 Last Updated in JCN: 111111

Entered Medline: 20021218

**AB** **Oligomerization** or dimerization of G-protein-coupled receptors (GPCRs) has emerged as an important theme in signal transduction. This concept has recently gained widespread interest due to the application of direct and innovative biophysical techniques such as fluorescence resonance energy transfer (FRET), which have shown unequivocally that several types of GPCR can form dimers or **oligomers** in living cells. Current challenges are to determine which GPCRs can self-associate and to interact with other GPCRs, to define the molecular principles that govern these specific interactions, and to establish which aspects of GPCR function require **oligomerization**. Although these questions are directly and indirectly addressed using GPCR-expressing cell lines in their native cell types, analysis of GPCR **oligomerization** in heterologous expression systems will be useful to survey which GPCRs can interact, to conduct structure-function studies, and to identify peptides or small molecules that disrupt GPCR **oligomerization** and function. Here, we describe methods employing scanning fluorimetry to report FRET between GPCRs tagged with enhanced cyan and yellow fluorescent proteins (EYFP and YFP) in living yeast cells. This approach provides a powerful means to analyze **oligomerization** of a variety of GPCRs that can be expressed in yeast, such as adrenergic, metabotropic, G<sub>i</sub>, muscarinic, serotonin 1A, vasopressin, opiate, and secretin receptors.

ACC. NUMBER: 20021218 MEDLINE  
 ABBREVIATION NUMBER: 20021218 MEDLINE  
 CURRENT NUMBER: 20021218 MEDLINE  
 TITLE: **Oligomerization** of GPCR is required for the generation of a functional red fluorescent chromophore.  
 AUTHOR: Marchetti Andrea; Subramaniam Vinod; Levin Thomas M; Alberti Gaveria  
 ORIGINATE SOURCE: Laboratory of Experimental Oncology, Department of Cell Biology and Oncology, Istituto di Ricerche Farmacologiche Mario Negri-Consortio Mario Negri Sud, 66100, Chieti, Santa Maria Imbaro, Italy.  
 SOURCE: FEBS LETTERS, 2002 Aug 14; 525 (1-3): 13-9.  
 Journal Code: 1568-2825, ISSN: 0164-5794.  
 PUB. COUNTRY: Netherlands  
 DOCUMENT TYPE: Journal; Article; JOURNAL ARTICLE  
 LANGUAGE: English  
 FILE SEGMENT: Full Text  
 ENTRY MONTH: 200209  
 ENTRY DATE: Entered STN: 20020917  
 Last Updated on STN: 20021218  
 Entered Medline: 20021218

**AB** The coral red fluorescent protein (DsRed) absorbs and emits light at much higher wavelengths than the structurally homologous **green** fluorescent protein, raising questions about the properties of its chromophore. We have analyzed the relationship between the aggregation state and fluorescence of native, c-histidine-tagged, or maltose-binding protein-fused DsRed. In all cases, newly synthesized DsRed molecules were largely monomeric and devoid of covalently closed chromophores. Maturation in vitro induces the expression of red **fluorescent** chromophores, but only in **oligomeric** forms of the **protein**, whereas monomers are essentially devoid of fluorescence. NaOH-denatured samples demonstrated a generalized breakdown of the labeled **oligomers** to monomers, which refolded after neutralization into weakly **green** fluorescent and still monomeric species. Red fluorescent chromophores were regenerated only upon **oligomerization**. These findings demonstrate that 'red'

File: 100-477

and its potential role in the secretory pathway of oligomers, and suggest that the small-sized secretory proteins may be a subset. A comparison of secretory, cytosolic and transmembrane proteins indicated that oligomerization of the secretory proteins may play a critical role in the secretory pathway.

LD: ANSWER - F 104 MEDLINE  
ABSTRACT NUMBER: 100-477 MEDLINE  
CURRENT NUMBER: 100-477 MEDLINE  
TITLE: Oligomerization of green fluorescent protein in the secretory pathway of endocrine cells.  
AUTHOR: Park P H; Lipp P B; Kuroda M; Hahn J A; Fair J W  
JOURNAL: J Molecular, Cellular and Physiol Biol 37, University of Louisville, 101 South Jackson Street, Louisville, KY 40202, U.S.A.  
DISPATCH NUMBER: 100-477 MEDLINE  
SOURCE: BIOCHEMICAL JOURNAL, Vol. 264, Pt 1, 1990, pp. 1-6.  
PUB. COUNTRY: England; United Kingdom  
DOCUMENT TYPE: Journal; Article; JOURNAL ARTICLE  
LANGUAGE: English  
FILE OF NAME: Oligomerization  
ENTRY NUMBER: 100-477  
ENTRY DATE: Entered STM: 10/11/90  
Last Updated in STM: 10/11/90  
Entered MEDLINE: 10/11/90

AB Green fluorescent protein (GFP) is used extensively as a reporter protein to monitor cellular processes, including intracellular protein trafficking and secretion. In general, this approach depends on GFP acting as a passive reporter protein. However, it was recently noted that GFP oligomerizes in the secretory pathway of endocrine cells. To characterize this oligomerization and its potential role in GFP transport, cytosolic and secretory forms of enhanced GFP (EGFP) were expressed in GH4C1 and AtT-21 endocrine cells. Biochemical analysis showed that cytosolic EGFP existed as a 7 kDa monomer, whereas secretory forms of EGFP formed disulfide-linked oligomers. EGFP contains two cysteine residues (Cys 49 and Cys 71), which may play a role in this oligomerization. Site-directed mutagenesis of Cys 49 and Cys 71 showed that both cysteine residues were involved in disulfide interactions. Substitution of either cysteine residue resulted in a reduction or loss of oligomers, although dimers of the secretory form of EGFP remained. Mutation of these residues did not adversely affect the release of EGFP. EGFP oligomers were stored in secretory granules and secreted by the regulated secretory pathway in endocrine AtT-21 cells. Similarly, the secretory granules of EGFP were still secreted via the regulated secretory pathway, indicating that the higher-order oligomers were not necessary for sorting in AtT-21 cells. These results suggest that the oligomerization of EGFP must be considered when the protein is used as a reporter molecule in the secretory pathway.

LD: ANSWER - F 104 MEDLINE  
ABSTRACT NUMBER: 100-477 MEDLINE  
CURRENT NUMBER: 100-477 MEDLINE  
TITLE: Oligomerization of the green fluorescent protein in the secretory pathway of endocrine cells.

Search completed by Linda Schneider 10/11/90

Page 1 of 1

ABSTRACT: TSHR reveals post-translational complexes.  
AUTHOR: Lavi E; Haver E; Lavi E F  
CORPORATE SOURCE: Division of Endocrinology, Diabetes and Bone Diseases,  
Mount Sinai School of Medicine, New York, New York  
10029-3074, USA. Email: lavi@msm.mssm.edu  
100 668196-11 NDRF  
SOURCE: JOURNAL OF CELLULAR PHYSIOLOGY, Vol 180, No 1, pp 4-11-1998.  
Journal Code: JCPH. ISSN: 0021-9594.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; JOURNAL ARTICLE  
LANGUAGE: English  
FILE COMMENT: Priority Journals  
ENTRY NUMBER: 21-101  
ENTRY DATE: Entered RTN: 21-10114  
Last Updated: 21-101  
Entered Medline: 21-1011

ABSTRACT: To examine thyrotropin (TSH) receptor (a heptahelical transmembrane protein) interactions we used the human TSH receptor (hTSHR) cDNA fused to a green fluorescent protein (GFP) and the corresponding chimeric cDNA was expressed in Chinese hamster ovary cells. Fluorescent TSH receptors in the plasma membrane were functional as assessed by TSH-induced cAMP formation. The clustering of TSHR, as well as TSHR autoantibodies, induced TSH- and dose-dependent receptor aggregation. Fluorescence resonance energy transfer between receptor is differentially altered with GFP variants (RFP and YFP) provided evidence for the close proximity of individual receptor molecules. This was consistent with previous studies demonstrating the presence of TSHR dimers and oligomers in thyroid tissue. Co-immunoprecipitation of GFP-tagged and Myc-tagged receptor complexes was performed using doubly transfected cells with Myc antibody. Western blotting of the immunoprecipitated complex revealed the absence of noncleaved TSHR holoreceptors. This further suggested that cleavage of the holoreceptor into its two-subunit structure, comprising disulfide-linked TSHR-alpha and TSHR-beta subunits, was required for the formation of TSHR dimers and higher order complexes.

LL: AINWFF - F.01 MEDLINE  
ACCESSION NUMBER: 21-1019271 MEDLINE  
DOCUMENT NUMBER: 21-101944 PubMed ID: 11-19274  
TITLE: Self-assembly and binding of a sorting nexin to sorting endosomes.  
AUTHOR: Korten R C; Eddington A J; Chowdhury P; Smith R L; Davidson A J; Shank B E  
CORPORATE SOURCE: Department of Physiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205-7500, USA.  
KortenR@uamsexchange.uams.edu  
SOURCE: JOURNAL OF CELL SCIENCE, 114 May, 114 1141-1141-16.  
Journal Code: JCS. ISSN: 0021-9594.  
PUB. COUNTRY: England; United Kingdom  
DOCUMENT TYPE: Journal; Article; JOURNAL ARTICLE  
LANGUAGE: English  
FILE COMMENT: Priority Journals  
ENTRY NUMBER: 21-101  
ENTRY DATE: Entered RTN: 21-101  
Last Updated: 21-101  
Entered Medline: 21-101

Abstract supplied by Linda Schneider 5-4-2004

AB The rate of endoplasmic reticulum protein and lipid synthesis is determined by a cellular processing system in eukaryotic cells. Endoplasmic reticulum is a specialized organelle within this compartment, and thereby prevents their recycling. We report that a certain member SNX1, a transmembrane protein, is involved in the processing of SNX1, a transmembrane protein, and has this property in common with other members of the SNX1 family. A transmembrane SNX1-expressing in bacterial and mammalian systems and analyzed by size-exclusion chromatography and showed that in vitro SNX1 tetramer is a part of a larger complex with lipid and protein. An endoplasmic reticulum SNX1 complex was purified from SNX1-expressing cells and membranes, yet the complexes that we analyzed were largely soluble and little SNX1 was found in pellet fraction. Using **green fluorescent protein fusions**, analytical ultracentrifugation and fluorescence recovery after photobleaching, we found that there is an equilibrium between free cytoplasmic and early sorting endoplasmic reticulum **green fluorescent protein-SNX1**. Fluorescence resonance energy transfer indicated that spectral variants of **green fluorescent protein-SNX1** were oligomeric in vivo. In cell extracts, these **green fluorescent protein-SNX1 oligomers** were found to be tetramers and dimers composed of **green fluorescent protein-SNX1**. Using wide angle X-ray scattering, we observed small vesicle binding and tubule binding to a **green fluorescent protein-SNX1** vesicle fusion assay, which are involved in the sorting of SNX1 to the endoplasmic reticulum. <http://www.sciencedirect.com/science/article/pii/S0021925800000000>

LAST AMENDED: 1/1/14  
 MEDLINE  
 ABBREVIATION NUMBER: 1/1/14  
 MEDLINE  
 DOCUMENT NUMBER: 1/1/14  
 MEDLINE  
 TITLE: **biochemistry, mutagenesis, and oligomerization of Isb-1, a red fluorescent protein from coral.**  
 AUTHOR: David G. S.; Zacharias D. A.; Tsien R. Y.  
 CORPORATE SOURCE: Department of Pharmacology, University of California, San Diego, La Jolla, CA 92037, USA.  
 CONTRACT NUMBER: N01-177 (NINDS)  
 SOURCE: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (2001) Oct 24, 98(26): 11364-8.  
 Journal code: 0027-9527, ISSN: 0027-9527.  
 PAF. COUNTRY: United States  
 PAYMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 1/1/14  
 ENTRY DATE: Entered STN: 1/1/14  
 Last Updated on STN: 1/1/14  
 Entered Medline: 1/1/14

AB Isb-1 is a recently cloned 24-kDa fluorescent protein responsible for the red coloration around the oral disk of a coral of the *Discoastera* genus. Isb-1 has attracted tremendous interest as a potential expression tracer and fusion partner that would be complementary to the homologous **green fluorescent protein** from *Aequorea*, but very little is known of the biochemistry of Isb-1. We now show that Isb-1 has a much higher extinction coefficient and quantum yield than previously reported, plus excellent resistance to pH extremes and proteolysis. In addition, the Isb-1 emission maximum can be further shifted to 650 nm by mutation of lys-100 to Met. However, Isb-1 has major drawbacks, such as strong **oligomerization** and slow maturation. Analytical ultracentrifugation shows Isb-1 to be an obligate tetramer in vitro, and

the polymerization of 2,2'-bipyridine and pyridine oligomers  
leading to **oligomerization** in some cases. Also, these  
oligomers are **green** in color. In addition, the  
polymerization of 2,2'-bipyridine and pyridine oligomers  
is a **slow** process. As a result, the **oligomers** may be  
used in **polymerization** reactions. These will require **exposure** to the  
light source and **exposure** to the **light** source.

both viruses use RNA as their genetic material within viral particles and DNA proviruses as their genetic material within cells. The rate of recombination during reverse transcription between two identical sequences within the same RNA molecule is very high. In this study, we have developed a sensitive system to study recombination occurring within the proviral sequence. This system includes a murine Moloney leukemia virus vector which contains a neomycin resistance gene (neo<sup>r</sup>) and two mutated green fluorescent protein genes (gfp) in tandem positions. The 3' end of the first gfp and the 5' end of the second gfp gene are both mutated, so that neither of these two gfp genes is functional. However, if recombination occurs between the two gfp genes it will create a functional gfp protein. Cells containing such a functional recombinant gfp appear green under fluorescence microcopy. The rate of recombination between the two gfp sequences during a single round of replication is as high as 10%. Green cells appear during proliferation of a clonal cleared-cell population and allow a small portion of these recombinations between sequences of proviral DNA to be detected. The frequency of recombination of the proviral DNA level is approx 10<sup>-5</sup> events/cell/division, which is very low compared with the frequency of recombination (0.1) caused by reverse transcriptase and/or RNA polymerase II.

Downloaded from <http://ajphaphapublications.sagepub.com/> by David Schneider on 05-14-2015

Page 1 of 1

Department of Biology, University College London, Gower Street, London WC1E 6BT, United Kingdom.  
JOURNAL OF CELL BIOLOGICAL CHEMISTRY, 1997, Vol. 18, No. 1, pp. 1-10.  
Journal Code: JCB1818. ISSN: 0021-9744.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; JOURNAL ARTICLE  
LANGUAGE: English  
FILE EXTENSION: .html  
ENTRY NUMBER: 10000  
ENTRY DATE: Entered JIN: 1997-01-17  
Last Update on JIN: 1997-01-17  
Entered Medline: 1997-01-17

AB The expanded polyglutamine (polyQ) domain with misfolding of glutathione S-transferase (GST) in the neurodegenerative primary open-angle glaucoma type 1 is caused by the presence of a common Pro11 --> Leu polymorphism and a disease-specific Gly17 --> Arg mutation. The Pro11 --> Leu replacement generates a functionally weak N-terminal mitochondrial targeting sequence (MTS), the efficiency of which is increased by the additional presence of the Gly17 --> Arg replacement. GST dimerization is inhibited in the presence of both replacement mutations when each is present separately. In this paper we have attempted to identify the structural determinants of GST dimerization and mitochondrial misfolding. Unlike most MTSs, the polymorphic MTS of GST has little tendency to form an alpha-helical conformation in vitro. Nevertheless, it does not target efficiently a non-membrane green fluorescent (GFP) fusion protein, but not dimeric GST, to mitochondria in transfected COS-1 cells. Increasing the propensity of this MTS to fold into an alpha-helix, by making a double Pro11 --> Leu + Pro17 --> Leu replacement, enabled it to target both GFP and GST efficiently to mitochondria. The double Pro11 --> Leu + Pro17 --> Leu replacement retarded GST dimerization in vitro as did the disease-causing double Pro11 --> Leu + Gly17 --> Arg replacement. These data suggest that N-terminal alpha-helix formation is more important for maintaining GST in a conformation (i.e. monomeric) compatible with mitochondrial import than it is for the provision of mitochondrial targeting information. The parallel effects of the Pro11 --> Leu and Gly17 --> Arg replacements on the dimerization and intracellular targeting of polymorphic GST containing the Pro11 --> Leu replacement raise the possibility that they might achieve their effects by the same mechanism.

KEY ANSWER OF JCB MEDLINE  
ACCESSION NUMBER: 97446032 MEDLINE  
ENTRY NUMBER: 97446032 PubMed ID: 9249559  
TITLE: Oligomerization of expanded-polyglutamine domain fluorescent fusion proteins in cultured mammalian cells.  
AUTHOR: Carrera G; Burke J B; Miller J E; Hester J; Teitel J; Bates A J; Strittmatter W J  
CORRESPONDENCE: Department of Medicine, Neurology, Duke University Medical Center, Durham, North Carolina 27710, USA.  
CONTACT NUMBER: 919-286-1400 FAX: 919-286-1400  
JOURNAL: JOURNAL OF CELL BIOLOGICAL CHEMISTRY, 1997, Vol. 18, No. 1, pp. 1-10.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; JOURNAL ARTICLE  
LANGUAGE: English



File: 1000000000

FILE NUMBER: 1000000000  
ENTRY NUMBER: 1000000000  
ENTRY DATE: 10/01/00  
Last Modified: 10/01/00  
Entry ID: 1000000000

AB The inherited neurodegenerative diseases, including Huntington's disease, result from the expansion of a CAG repeat in the disease gene. To provide a model for the pathogenesis of these diseases, we expressed a full-length polyglutamine protein in the expression system. The mechanism by which expansion of this polyglutamine domain causes disease is unknown. Several studies have indicated **oligomerization** of polyglutamine-containing proteins in mammalian cells. To study **oligomerization** of polyglutamine proteins and to identify potential protein interactions, varying lengths of polyglutamine-green fluorescent protein fusion proteins were expressed in cultured cells. The 12- and 25-glutamine fusion proteins formed stable, soluble oligomers distributed diffusely throughout the cytoplasm. In contrast, 36- and 48-glutamine fusion proteins formed long, thin, fibrillar arrays resembling those previously observed in neurons in Huntington's disease and in a transgenic mouse model. These aggregates were intranuclear and intracytoplasmic. Intracytoplasmic aggregates were surrounded by oligomeric intermediate filaments. The intermediate filament protein vimentin co-localized with expanded polyglutamine fusion proteins. This cellular model will expedite investigations into **oligomerization** of polyglutamine proteins and their interactions with other proteins.

Copyright 1999 Academic Press.

1000000000 1000000000 1000000000 1000000000 1000000000  
AUTHOR(S): 1000000000 1000000000  
COMMENT NUMBER: 1000000000  
TITLE: Systemically delivered antisense oligomers upregulate gene expression in mouse tissues  
AUTHOR(S): Nazani, Peter; Geminiani, Federica; Kang, Shin-Hong; Maier, Martin A.; Manoharan, Muthiah; Fersmark, Magnus; Bortner, Donna; Kole, Ryszard  
CORRESPONDENCE: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 27599, USA  
SOURCE: Nature Biotechnology 17(12), 1248-1253  
CODEN: NABIF9; ISSN: 1087-0116  
PUBLISHER: Nature Publishing Group  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Systemically injected 2'-O-methoxyethyl 2'-O-methyl-phosphorothioate and RNA-4K oligomers (peptide **nucleic acid** with four lysines linked at the 3' terminus) exhibited sequence-specific antisense activity in a number of mouse organs. Morpholino oligomers were less effective, whereas RNA oligomers with only the lysine (RNA-1K) were completely inactive. The latter result indicates that the four-lysine tail is essential for the antisense activity of RNA oligomers in vivo. These results were obtained in a transgenic mouse model designed as a positive readout test for activity, delivery, and distribution of antisense oligomers. In this model, the expression of EGF-64 encoding enhanced **green fluorescent protein** (EGFP) is interrupted by an aberrantly spliced mutant intron of the human EGF-64 gene. Aberrant splicing of this intron prevented expression of EGFP-64 in all tissues, whereas in tissues and organs that express a splicing factor, antisense oligomers, correct splicing was restored and EGFP-64 expression upregulated. The sequence-specific activity of RNA-4K and the 2'-O-methyl oligomers to upregulate EGFP-64 provides strong evidence that systemically delivered, chem. modified

[illegible][illegible]

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2423	2424	2425	2426	2427	2428	2429	2430	2431	2432	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

$\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & -i \\ 0 & 0 \end{pmatrix}$	$\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & i \\ 0 & 0 \end{pmatrix}$	$\frac{1}{\sqrt{2}} \begin{pmatrix} 0 & 0 \\ 1 & 0 \end{pmatrix}$	$\frac{1}{\sqrt{2}} \begin{pmatrix} 0 & 0 \\ 1 & 0 \end{pmatrix}$
$\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & 0 \\ 0 & 0 \end{pmatrix}$	$\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & 0 \\ 0 & 0 \end{pmatrix}$	$\frac{1}{\sqrt{2}} \begin{pmatrix} 0 & 0 \\ 1 & 0 \end{pmatrix}$	$\frac{1}{\sqrt{2}} \begin{pmatrix} 0 & 0 \\ 1 & 0 \end{pmatrix}$
$\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & 0 \\ 0 & 0 \end{pmatrix}$	$\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & 0 \\ 0 & 0 \end{pmatrix}$	$\frac{1}{\sqrt{2}} \begin{pmatrix} 0 & 0 \\ 1 & 0 \end{pmatrix}$	$\frac{1}{\sqrt{2}} \begin{pmatrix} 0 & 0 \\ 1 & 0 \end{pmatrix}$

[illegible]

dimeric fluorescent

protein

1. The first part of the paper is a review of the literature on the effects of the 1997 Asian financial crisis on the economies of the Asian countries. It shows that the crisis had a significant negative impact on the economies of the Asian countries, particularly on the economies of the newly industrialized countries (NICs). The second part of the paper is a review of the literature on the effects of the 1997 Asian financial crisis on the economies of the Asian countries. It shows that the crisis had a significant negative impact on the economies of the Asian countries, particularly on the economies of the newly industrialized countries (NICs).

[illegible]

Table 1. *Phylogenetic relationships of the studied species*

Species	Accession Number	GenBank
<i>Phytophthora blight</i>	AY123456	GenBank
<i>Phytophthora blight</i>	AY123457	GenBank
<i>Phytophthora blight</i>	AY123458	GenBank
<i>Phytophthora blight</i>	AY123459	GenBank
<i>Phytophthora blight</i>	AY123460	GenBank
<i>Phytophthora blight</i>	AY123461	GenBank
<i>Phytophthora blight</i>	AY123462	GenBank
<i>Phytophthora blight</i>	AY123463	GenBank
<i>Phytophthora blight</i>	AY123464	GenBank
<i>Phytophthora blight</i>	AY123465	GenBank
<i>Phytophthora blight</i>	AY123466	GenBank
<i>Phytophthora blight</i>	AY123467	GenBank
<i>Phytophthora blight</i>	AY123468	GenBank
<i>Phytophthora blight</i>	AY123469	GenBank
<i>Phytophthora blight</i>	AY123470	GenBank
<i>Phytophthora blight</i>	AY123471	GenBank
<i>Phytophthora blight</i>	AY123472	GenBank
<i>Phytophthora blight</i>	AY123473	GenBank
<i>Phytophthora blight</i>	AY123474	GenBank
<i>Phytophthora blight</i>	AY123475	GenBank
<i>Phytophthora blight</i>	AY123476	GenBank
<i>Phytophthora blight</i>	AY123477	GenBank
<i>Phytophthora blight</i>	AY123478	GenBank
<i>Phytophthora blight</i>	AY123479	GenBank
<i>Phytophthora blight</i>	AY123480	GenBank
<i>Phytophthora blight</i>	AY123481	GenBank
<i>Phytophthora blight</i>	AY123482	GenBank
<i>Phytophthora blight</i>	AY123483	GenBank
<i>Phytophthora blight</i>	AY123484	GenBank
<i>Phytophthora blight</i>	AY123485	GenBank
<i>Phytophthora blight</i>	AY123486	GenBank
<i>Phytophthora blight</i>	AY123487	GenBank
<i>Phytophthora blight</i>	AY123488	GenBank
<i>Phytophthora blight</i>	AY123489	GenBank
<i>Phytophthora blight</i>	AY123490	GenBank
<i>Phytophthora blight</i>	AY123491	GenBank
<i>Phytophthora blight</i>	AY123492	GenBank
<i>Phytophthora blight</i>	AY123493	GenBank
<i>Phytophthora blight</i>	AY123494	GenBank
<i>Phytophthora blight</i>	AY123495	GenBank
<i>Phytophthora blight</i>	AY123496	GenBank
<i>Phytophthora blight</i>	AY123497	GenBank
<i>Phytophthora blight</i>	AY123498	GenBank
<i>Phytophthora blight</i>	AY123499	GenBank
<i>Phytophthora blight</i>	AY123500	GenBank

[illegible][illegible]

... ..

1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 26

01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	00																																																																																																																																																																																																																																																																																																																																																																																																																																																																													
AA	AB	AC	AD	AE	AF	AG	AH	AI	AJ	AK	AL	AM	AN	AO	AP	AQ	AR	AS	AT	AU	AV	AW	AX	AY	AZ	BA	BB	BC	BD	BE	BF	BG	BH	BI	BJ	BK	BL	BM	BN	BO	BP	BQ	BR	BS	BT	BV	BW	BX	BY	BZ	CA	CB	CC	CD	CE	CF	CG	CH	CI	CJ	CK	CL	CM	CN	CO	CP	CQ	CR	CS	CT	CU	CV	CW	CX	CY	CZ	DA	DB	DC	DD	DE	DF	DG	DH	DI	DJ	DK	DL	DM	DN	DO	DP	DQ	DR	DS	DT	DU	DV	DW	DX	DY	DZ	EA	EB	EC	ED	EE	EF	EG	EH	EI	EJ	EK	EL	EM	EN	EO	EP	EQ	ER	ES	ET	EU	EV	EW	EX	EY	EZ	FA	FB	FC	FD	FE	FF	FG	FH	FI	FJ	FK	FL	FM	FN	FO	FP	FQ	FR	FS	FT	FU	FV	FW	FX	FY	FZ	GA	GB	GC	GD	GE	GF	GG	GH	GI	GJ	GK	GL	GM	GN	GO	GP	GQ	GR	GS	GT	GU	GV	GW	GX	GY	GZ	HA	HB	HC	HD	HE	HF	HG	HH	HI	HJ	HK	HL	HM	HN	HO	HP	HQ	HR	HS	HT	HU	HV	HW	HX	HY	HZ	IA	IB	IC	ID	IE	IF	IG	IH	II	IJ	IK	IL	IM	IN	IO	IP	IQ	IR	IS	IT	IU	IV	IW	IX	IY	IZ	JA	JB	JC	JD	JE	JF	JG	JH	JI	IJ	JK	JL	JM	JN	JO	JP	JQ	JR	JS	JT	JU	JV	JW	JX	JY	JZ	KA	KB	KC	KD	KE	KF	KG	KH	KI	KJ	KK	KL	KM	KN	KO	KP	KQ	KR	KS	KT	KU	KV	KW	KX	KY	KZ	LA	LB	LC	LD	LE	LF	LG	LH	LI	LJ	LK	LL	LM	LN	LO	LP	LQ	LR	LS	LT	LU	LV	LW	LX	LY	LZ	MA	MB	MC	MD	ME	MF	MG	MH	MI	MJ	MK	ML	MN	MO	MP	MQ	MR	MS	MT	MU	MV	MW	MX	MY	MZ	NA	NB	NC	ND	NE	NF	NG	NH	NI	NJ	NK	NL	NM	NN	NO	NP	NQ	NR	NS	NT	NU	NV	NW	NX	NY	NZ	OA	OB	OC	OD	OE	OF	OG	OH	OI	OJ	OK	OL	OM	ON	OO	OP	OQ	OR	OS	OT	OU	OV	OW	OX	OY	OZ	PA	PB	PC	PD	PE	PF	PG	PH	PI	PJ	PK	PL	PM	PN	PO	PP	PQ	PR	PS	PT	PU	PV	PW	PX	PY	PZ	QA	QB	QC	QD	QE	QF	QG	QH	QI	QJ	QK	QL	QM	QN	QO	QP	QQ	QR	QS	QT	QU	QV	QW	QX	QY	QZ	RA	RB	RC	RD	RE	RF	RG	RH	RI	RJ	RK	RL	RM	RN	RO	RP	RQ	RR	RS	RT	RU	RV	RW	RX	RY	RZ	SA	SB	SC	SD	SE	SF	SG	SH	SI	SJ	SK	SL	SM	SN	SO	SP	SQ	SR	SS	ST	SU	SV	SW	SX	SY	SZ	TA	TB	TC	TD	TE	TF	TG	TH	TI	TJ	TK	TL	TM	TN	TO	TP	TQ	TR	TS	TU	TV	TW	TX	TY	TZ	UA	UB	UC	UD	UE	UF	UG	UH	UI	UJ	UK	UL	UM	UN	UO	UP	UQ	UR	US	UT	UU	UV	UW	UX	UY	UZ	VA	VB	VC	VD	VE	VF	VG	VH	VI	VJ	VK	VL	VM	VN	VO	VP	VQ	VR

AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BX, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DC, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GG, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LL, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MM, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NN, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UU, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ

AD 2-1230923	AD 2302-0024	AD 2302-30920	230311413
--------------	--------------	---------------	-----------

18 800-256-215 256-215

DOI: 10.1002/for

AB The invention relates to proteins or polypeptides that comprise intramolecular dimers of fluorescent protein molecules. More specifically, the invention relates to recombinant polypeptides comprising a monomer of a fluorescent polypeptide, a linker peptide, and a second monomer of said fluorescent polypeptide, where the monomers form an intramolecular dimer. The invention also relates to nucleic acids

### Abstract: Dimer Fluorescent Proteins

fluorescent molecules, either fluorochrome proteins (IFPs) and/or those comprising such a nucleic acid. The invention further relates to methods of making IFPs and methods of using them. IFPs are useful in any application suited for fluorescent proteins and are particularly useful in applications in which more than one fluorescent protein should complementarily

dimerization

1. *Pharmaceutical industry* – The pharmaceutical industry is the largest of the three industries, with sales of \$10.5 billion in 1997. It is the only industry that has not experienced a decline in sales since 1990. The industry is dominated by a few large firms, with the top five firms accounting for 40% of sales. The industry is highly competitive, with many firms competing for market share. The industry is also highly regulated, with the FDA overseeing the approval of new drugs. The industry is expected to continue to grow, with sales projected to reach \$12.5 billion by 2000.

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

Table 1. *Continued*

1. *Journal of the American Medical Association*, 1997; 277: 1033-1036.

Figure 1. Schematic representation of the experimental design. The subjects were divided into two groups: the control group and the experimental group. The control group received a standard diet and water, while the experimental group received a diet supplemented with 0.5% of the active ingredient. The subjects were then subjected to a series of tests: a pre-test, a 1st test, a 2nd test, and a 3rd test. The results of the tests were then compared between the two groups.

NOTE: The following information is provided for informational purposes only and is not intended to be used for the purpose of providing or receiving services. The information is provided for informational purposes only and is not intended to be used for the purpose of providing or receiving services.

[illegible]

... ..

DATE	TIME	REMARKS	DATE
1954-11-14	11:00	11:00-11:15	11:15-11:30
1954-11-14	11:15	11:15-11:30	11:30-11:45
1954-11-14	11:30	11:30-11:45	11:45-12:00
1954-11-14	11:45	11:45-12:00	12:00-12:15
1954-11-14	12:00	12:00-12:15	12:15-12:30
1954-11-14	12:15	12:15-12:30	12:30-12:45
1954-11-14	12:30	12:30-12:45	12:45-13:00
1954-11-14	12:45	12:45-13:00	13:00-13:15
1954-11-14	13:00	13:00-13:15	13:15-13:30
1954-11-14	13:15	13:15-13:30	13:30-13:45
1954-11-14	13:45	13:45-14:00	14:00-14:15
1954-11-14	14:00	14:00-14:15	14:15-14:30
1954-11-14	14:15	14:15-14:30	14:30-14:45
1954-11-14	14:45	14:45-15:00	15:00-15:15
1954-11-14	15:00	15:00-15:15	15:15-15:30
1954-11-14	15:15	15:15-15:30	15:30-15:45
1954-11-14	15:45	15:45-16:00	16:00-16:15
1954-11-14	16:00	16:00-16:15	16:15-16:30
1954-11-14	16:15	16:15-16:30	16:30-16:45
1954-11-14	16:45	16:45-17:00	17:00-17:15
1954-11-14	17:00	17:00-17:15	17:15-17:30
1954-11-14	17:15	17:15-17:30	17:30-17:45
1954-11-14	17:45	17:45-18:00	18:00-18:15
1954-11-14	18:00	18:00-18:15	18:15-18:30
1954-11-14	18:15	18:15-18:30	18:30-18:45
1954-11-14	18:45	18:45-19:00	19:00-19:15
1954-11-14	19:00	19:00-19:15	19:15-19:30
1954-11-14	19:15	19:15-19:30	19:30-19:45
1954-11-14	19:45	19:45-20:00	20:00-20:15
1954-11-14	20:00	20:00-20:15	20:15-20:30
1954-11-14	20:15	20:15-20:30	20:30-20:45
1954-11-14	20:45	20:45-21:00	21:00-21:15
1954-11-14	21:00	21:00-21:15	21:15-21:30
1954-11-14	21:15	21:15-21:30	21:30-21:45
1954-11-14	21:45	21:45-22:00	22:00-22:15
1954-11-14	22:00	22:00-22:15	22:15-22:30
1954-11-14	22:15	22:15-22:30	22:30-22:45
1954-11-14	22:45	22:45-23:00	23:00-23:15
1954-11-14	23:00	23:00-23:15	23:15-23:30
1954-11-14	23:15	23:15-23:30	23:30-23:45
1954-11-14	23:45	23:45-24:00	24:00-24:15
1954-11-14	24:00	24:00-24:15	24:15-24:30
1954-11-14	24:15	24:15-24:30	24:30-24:45
1954-11-14	24:45	24:45-25:00	25:00-25:15
1954-11-14	25:00	25:00-25:15	25:15-25:30
1954-11-14	25:15	25:15-25:30	25:30-25:45
1954-11-14	25:45	25:45-26:00	26:00-26:15
1954-11-14	26:00	26:00-26:15	26:15-26:30
1954-11-14	26:15	26:15-26:30	26:30-26:45
1954-11-14	26:45	26:45-27:00	27:00-27:15
1954-11-14	27:00	27:00-27:15	27:15-27:30
1954-11-14	27:15	27:15-27:30	27:30-27:45
1954-11-14	27:45	27:45-28:00	28:00-28:15
1954-11-14	28:00	28:00-28:15	28:15-28:30
1954-11-14	28:15	28:15-28:30	28:30-28:45
1954-11-14	28:45	28:45-29:00	29:00-29:15
1954-11-14	29:00	29:00-29:15	29:15-29:30
1954-11-14	29:15	29:15-29:30	29:30-29:45
1954-11-14	29:45	29:45-30:00	30:00-30:15
1954-11-14	30:00	30:00-30:15	30:15-30:30
1954-11-14	30:15	30:15-30:30	30:30-30:45
1954-11-14	30:45	30:45-31:00	31:00-31:15
1954-11-14	31:00	31:00-31:15	31:15-31:30
1954-11-14	31:15	31:15-31:30	31:30-31:45
1954-11-14</			

[illegible]

AP The present invention relates to nucleic acids encoding S11  
labeled interfering RNA polypeptides; minimal fragments of hepatitis  
B virus proteins responsible for specific interactions with proteins of  
the virus. These peptides and their interactions may be targets for  
prevention and treatment of infection of hepatitis B virus. The invention  
also includes vectors comprising a nucleic acid encoding a S11  
polypeptide as well as host cells transformed with such vectors. The  
invention is also directed to yeast or bacterial two-hybrid methods which  
make use of the nucleic acids encoding a S11 polypeptide  
selected from a pathogenic strain of the hepatitis B virus as well as to  
methods for selecting moles, which inhibit the binding between a S11  
polypeptide and a polypeptide which specifically binds thereto.  
Protein-protein interactions of S11 polypeptides may be detected by  
covalent or non-covalent attachment of  
fluorescent proteins, labeled antibodies or enzymes with  
catalytic activity to one S11 polypeptide 'marker protein' and  
subsequently contacting the marker protein with a plurality of other  
proteins like S11 polypeptides. The S11 polypeptides may also be  
covalently linked to a spacer, which may also be covalently bound to a  
substrate to immobilize the S11 polypeptides. For example, the S11  
polypeptide may be attached to biotin when the substrate is streptavidin.  
Changes in optical properties of the substrate, following binding by S11  
polypeptides are detected. S11 polypeptides can be used in vaccines for  
prevention and treatment of hepatitis B virus in animals or humans.

10.5 ANSWER: 17.83 24. HCAELM. COPYRIGHT 2003 APS

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains. The *Agrobacterium* strains were cultured in the YEA medium for 24 h and then adjusted to the concentration of  $1 \times 10^8$  cells/ml. The *Agrobacterium* strains were then cultured in the YEA medium with the concentration of 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 cells/ml. The transformation efficiency was determined by the number of transformants per 100 cells. The results are shown in Table 1.

SECRET 145-6764

TITLE: Single molecule imaging of green fluorescent proteins in living cells: E-cadherin forms oligomers on the cell cell surface

AUTHOR : Iino, Ryota; Koyama, Ikuko; Kusumi, Akihiko  
 CORPORATE SOURCE: Kusumi Membrane Organizer Project, Exploratory  
 Research for Advanced Technology Organization, Japan  
 Science and Technology Corporation, Nagaoka, 81-0201,  
 Japan

1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 26

**PUBLISHER:** Biophysical Society  
**DOCUMENT TYPE:** Journal  
**LANGUAGE:** English

**AB** Small green fluorescent protein (GFP) molecules were successfully imaged for the first time in living cells. GFP linked to the cytoplasmic carboxyl terminus of E-cadherin (E-cad-GFP) was expressed in mouse fibroblast L cells, and used during an objective-type optical internal reflectivity (OIR) microscope setup. Based on the fluorescence intensity of individual oligomeric spots, the majority of E-cad-GFP exists in the cell surface as a monomer and a few oligomers. In addition, many oligomers were found in the cytoplasm, suggesting that oligomerization of E-cadherin takes place not only in the vicinity of cell-cell adhesion sites. The translational diffusion coefficient of E-cad-GFP is relatively a factor of 10<sup>-1</sup> to 10<sup>-2</sup> of oligomerization. Because such large decreases in translational mobility cannot be explained solely by increases in radius upon oligomerization, an oligomerization-induced trapping mechanism is proposed in which, when oligomers are formed, they are trapped in place due to greatly enhanced tumbling and rotational efforts of the membrane skeleton of oligomers compared with monomers. The presence of many oligomers greater than dimers in the cell surface suggests that these greater oligomers are the major oligomeric forms in the two-dimensional cell membrane structure and function domains.

**REFERENCE COUNT:** 1 THERE ARE 1 OTHER REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

**1. ANSWER 1: 0.1 HAWKINS COPYRIGHT 2000 ACM**  
**ARTICLE NUMBER:** 1011:1011-1011 HAWKINS  
**DOCUMENT NUMBER:** 1011:1011  
**TITLE:** Collective effects in individual oligomers of the red fluorescent coral protein IsRed

**AUTHOR(S):** Cotlet, M.; Hofkens, J.; Kohn, F.; Michiels, J.; Pirix, G.; Van Guyse, M.; Vanderlinden, J.; De Schryver, F. C.

**ORGANIZATIONAL SOURCE:** Department of Chemistry, Katholieke Universiteit Leuven, Heverlee, 3001, Belg.

**JOURNAL:** Chemical Physics Letters 2001, 331:1-4, 411-414  
**CODEN:** CHELBC; ISSN: 0009-2614

**PUBLISHER:** Elsevier Science B.V.  
**DOCUMENT TYPE:** Journal  
**LANGUAGE:** English

**AB** We report on single-mol. expts. that were performed on two biol. systems, the recently cloned red fluorescent protein of a coral of the *Lisotrema* genus (IsRed) and the enhanced green fluorescent protein, both of which were immobilized in polyvinyl alc. Fluorescence intensity transient rates were recorded and compared to those of a red. chem., the 1,1'-bis(4-dimethylaminophenyl)benzene-pyrene-9,10-imide. Evidence was found for the presence of linked as an oligomer even at sub-nanomolar concns. Both proteins show triple blinking in the millisecond time range. All blinking events could be ascribed to the IsRed oligomers.

**REFERENCE COUNT:** 14 THERE ARE 14 OTHER REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

**1. ANSWER 1: 0.1 HAWKINS COPYRIGHT 2000 ACM**  
**ARTICLE NUMBER:** 1011:1011-1011 HAWKINS  
**DOCUMENT NUMBER:** 1011:1011  
**TITLE:** Oligomerization of the human red protein

Page 1 of 1

transporter and of the rat 5HTA transporter. I  
visualized by fluorescence resonance energy transfer  
microscopy in living cells  
AUTHOR(S):  
Chen, Yuhong A.; Chishti, Iqbal; Marlowe, David;  
Friedman, Michael; Cooper, Brian A.; Lipp, Harald  
E.  
INSTITUTE/JOURNAL:  
Department of Vascular Biology and Translational  
Research, University of Vienna Medical School, Vienna,  
Austria  
JOURNAL:  
Journal of Biological Chemistry 277, 12111-12117,  
1992  
CITATION: 1992; 12111-12117  
PUBLISHER:  
American Society for Biochemistry and Molecular  
Biology  
DOCUMENT TYPE:  
Journal  
LANGUAGE:  
English

ABSTRACT: Previous studies indicate that the serotonin transporter can form  
oligomers. We investigated whether the human serotonin  
transporter (hSERT) can be visualized as an oligomer in the  
plasma membrane of intact cells. For this purpose, we generated fusion  
proteins of hSERT and spectral variants of the green fluorescent  
protein (GFP) and yellow fluorescent proteins, YFP and YFP, respectively. When  
expressed in human embryonic kidney 293 cells, the resulting fusion  
proteins YFP-hSERT and YFP-hSERT were efficiently inserted into the  
plasma membrane and were functionally indistinguishable from wild-type  
hSERT. Oligomers were visualized by fluorescence resonance  
energy transfer microscopy in living cells using two complementary  
methods, i.e., confocal imaging and cross-linking. Interestingly,  
oligomerization was not limited to hSERT; the resonance resonance  
energy transfer was also seen between YFP- and YFP-labeled rat  
5HTA-aminotransporter. The bulk of serotonin transporters  
was recovered as high mol. wt. complexes upon gel filtration in detergent  
solutions. In contrast, the monomers of YFP-hSERT and YFP-hSERT were  
essentially undetectable. This indicates that the homo-oligomeric  
form is the favored state of hSERT in living cells, which is not  
significantly affected by coinubation with transporter substrates or  
blockers. Based on our observations, we conclude that constitutive  
oligomer formation might be a general property of  
Na<sup>+</sup>/K<sup>+</sup>-dependent neurotransmitter transporters.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2: ANSWER 2 OF 24 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:07949 HCAPLUS

DOCUMENT NUMBER: 17435123

TITLE: FROM proximity imaging of green fluorescent  
protein-tagged polypeptides

AUTHOR(S):  
De Angelis, Ian A.; Klossner, John; Finkelstein, David  
V.; Rothman, James E.

INSTITUTE/JOURNAL:  
Cellular Biochemistry and Biophysics Program, Memorial  
Sloan-Kettering Cancer Center, New York, NY, 10021,  
USA

JOURNAL:  
Proceedings of the National Academy of Sciences of the  
United States of America 89, 12111-12117, 1992-1992  
CITATION: 1992; 12111-12117

PUBLISHER:  
National Academy of Sciences

DOCUMENT TYPE:  
Journal

LANGUAGE:  
English

ABSTRACT: We report a serendipitous discovery that extends the impressive catalog of



Fluorescence anisotropy decay microscopy was used to determine, in individual living cells, the spatial monomer-dimer distribution of proteins, as exemplified by herpes simplex virus thymidine kinase (TK) fused to green fluorescent protein (GFP). Accordingly, the fluorescence anisotropy dynamics of two fusion proteins, TK266GFP and TK366GFP, was recorded in the confocal mode by ultra-sensitive time-correlated single-photon counting. This provided a measurement of the rotational time of these proteins, which, by comparing with GFP, allowed the determination of their oligomeric state in both the cytoplasm and the nucleus. It also revealed energy homo-transfer within aggregates that TK366GFP progressively formed. Using a symmetric dimer model, structural parameters were estimated: the mutual orientation of the transition dipoles of the two GFP chromophores, calculated from the rotational anisotropy, was  $44.6 \pm 1.6$  degree, and the upper intermolecular limit between the two fluorescent tags, calculated from the energy transfer rate, was  $22$  Å. Acquisition of the fluorescence steady-state intensity, lifetime, and anisotropy decay in the same cells, at different times after transfection, indicated that TK366GFP was initially in a monomeric state and then formed dimers that grew into aggregates. Fluorescence-resolved fluorescence anisotropy microscopy opens a promising window for obtaining structural information on proteins in individual living cells, even when expressed at levels as very low.

DOI: ANSWER TO: 16-18 BIOSIS COPYRIGHT 2018 BIOLOGICAL ABSTRACTS INC.  
 ANSWER NUMBER: 17-1472174 BIOSIS  
 DOCUMENT NUMBER: PREVIEW00461472174  
 TITLE: A novel nuclear receptor x heterodimerization pathway mediated by orphan receptors TR1 and TR4.  
 AUTHOR(S): Lu, Ting-Hao; Thirupaidi, Chaitani; Wei, Li-Na; Li, Jia; Thirumangalakudi, Thir. Minnesota, 55455 Millard Hall, 4th Floor, St. Paul, MN 55455 USA  
 SOURCE: Journal of Biological Chemistry, Sept. 19, 2018 Vol. 293, No. 38, pp. 12412-12424.

Journal of Management Inquiry 20(1) 3-14 © 2011 Sage Publications  
10.1177/1056492610394222 jmi.sagepub.com



1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 2679, 26

Age Group	Total	Female	Male	Unknown
18-24	100	85	15	0
25-34	100	75	25	0
35-44	100	85	15	0
45-54	100	75	25	0
55-64	100	85	15	0
65+	100	75	25	0

FILE NUMBER: 100-441100; SUBJECT: MURKIN; RE: ALLEGED ATTEMPT TO  
OBTAIN INFORMATION ON MARTIN LUTHER KING, JR.

Figure 6 shows the effect of the initial concentration of the monomer on the polymerization rate. The reaction rate increases with increasing initial concentration of the monomer.